Trial Profile
An open label exploratory study to evaluate the safety, pharmacokinetics and efficacy of CRN00808 in patients with acromegaly treated with somatostatin analogue based treatment regimens (ACROBAT EDGE)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Nov 2022
Price :
$35
*
At a glance
- Drugs Paltusotine (Primary)
- Indications Acromegaly
- Focus Therapeutic Use
- Acronyms ACROBAT EDGE
- Sponsors Crinetics Pharmaceuticals
- 10 Nov 2022 Results assessing efficacy and safety in patients switched from octreotide LAR or lanreotide depot monotherapy to paltusotine, published in the Journal of Clinical Endocrinology and Metabolism.
- 23 Mar 2021 Results presented at the 103rd Annual Meeting of the Endocrine Society
- 22 Mar 2021 Results published in the Media Release